A prospective, single centre, phase II study to evaluate chronomodulated capecitabine and oxaliplatin (XELOX) regimen in untreated metastatic colorectal cancer patients

Trial Profile

A prospective, single centre, phase II study to evaluate chronomodulated capecitabine and oxaliplatin (XELOX) regimen in untreated metastatic colorectal cancer patients

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2017

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jul 2017 New trial record
    • 01 Jul 2017 All the patients have been treated between September 2012 and September 2014, according to an article published in the Cancer Chemotherapy and Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top